50 results about "Vaccine Potency" patented technology

The invention relates to the technical field of biological medicine, in particular to stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition and a preparation method and application of the vaccine composition. The invention provides a porcine pseudorabies virus gD recombinant protein capable of being stably expressed. The amino acid sequence of the porcine pseudorabies virus gD recombinant protein is shown as SEQ ID NO: 7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, the passage frequency is stable, and when 48 generations are continuously passed, the porcine pseudorabies virus gD recombinant protein still has good protein expression quantity. And a good foundation is laid for subsequent application in preparation of a stable porcine pseudorabies subunit vaccine composition or a porcine pseudorabies virus vaccine potency test preparation.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention belongs to the technical field of biology, and particularly relates to a hybridoma cell strain capable of secreting a clostridium perfringens ETX monoclonal antibody with neutralizing activity and application of the hybridoma cell strain. On the basis of natural toxin, an indirect ELISA (enzyme-linked immunosorbent assay) detection method is established by utilizing a non-toxic ETX single amino acid site protein mutant, and a series of hybridoma cell strains secreting an anti-clostridium perfringens ETX monoclonal antibody are screened; the hybridoma cell strain can stably and efficiently secrete a monoclonal antibody with neutralizing activity and a monoclonal antibody without neutralizing resistance respectively, and large-scale batch production can be realized. According to the present invention, the clostridium perfringens ETX monoclonal antibody is firstly utilized to establish the ETX antigen ELISA detection method, and the method has characteristics of simple sample operation, low cost, rapid reaction, strong specificity and the like, can provide the reference for the diagnosis of clostridium perfringens, and provides the basis for the research of the related vaccine potency test substitution method.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

The purpose of the present invention is to provide a new marker that indicates the relevance between a vaccine and the immunity of a subject inoculated with the vaccine. More specifically, the purpose of the present invention is to provide, for example, a method for determining the waning of vaccine effect using a new marker correlated with a tendency of vaccine effect to wane. The problem is solved by providing a method for determining the waning of vaccine effect, the method comprising a step for detecting a mutation in an immunoglobulin heavy-chain region in DNA contained in a sample from a subject, wherein, when the mutation is detected in the immunoglobulin heavy-chain region, the vaccine effect in the subject is determined to have a high tendency to wane.

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Devices and methods are described for utilizing occlusive dressings in combination with topical medicaments to enhance the efficacy of vaccines. The occlusive dressing delivers a defined dose of a topical medicament that enhances the immune system responsiveness of the vaccine to the vaccination site and provides a barrier that maintains the topical medicament layer on the skin for a desired period of time while also providing a port through which the immunization composition can be administered. In some embodiments, the occlusive dressing comprises a wound dressing used to cover the injection site after vaccination.

The invention discloses an mRNA (messenger Ribonucleic Acid) vector for in-vitro transcription as well as a construction method and application thereof, and relates to the technical field of gene engineering, and the technical key point is that the mRNA vector comprises the following gene segments: 5 'UTR (Untranslated Region), signal peptide, 3' UTR and polyadenylate tail; 5 'UTR is 70 nt or Ces1d; the signal peptide is Igk or tPAP22A; the 3 'UTR is ApoA-II or AP3B1; the polyadenylic acid is PolyA (40 + 10 + 60) or PolyA (30 + 10 + 70); the invention further provides a construction method of the mRNA vector recombinant plasmid, a cell containing the mRNA vector, a recombinant bacterium containing the mRNA vector, and an application of the mRNA vector, the cell and the recombinant bacterium in in-vitro transcription. According to the mRNA vaccine vector provided by the invention, by optimizing the vector element, the stability and translation efficiency of the vector element can be improved, meanwhile, the vaccine efficacy is improved, and an important technical support is provided for future vaccine development and disease prevention and control.

The invention discloses a novel immune enhancement system, which comprises a specific TLR4 agonistic polypeptide and a CD40 single-domain antibody. According to the polypeptide, a KLAKLAK core module is adopted, penetrating peptide and hydrophobic groups are modified, and an NF-kappa B / MAPK pathway can be effectively activated; the antibody is obtained through shark immune screening and has high affinity to CD40. When in combined application, the GM-CSF / IL-4-containing medium synergistically promotes the maturation of dendritic cells, so that the expression of CD80 / CD86 / MHC-II is improved by more than 2 times, the secretion amount of IL-12 reaches 165 pg / mL, and the proliferation rate of T cells is improved to 48.6%. Animal experiments show that the T cell stimulation index of a combined group reaches 6.2, and the serum IFN-gamma level is improved by 9 times. The composition provided by the invention can significantly enhance the DC vaccine efficacy, and has important application value in the field of tumor immunotherapy.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

This invention relates to the field of biomedical technology, specifically to a stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition, its preparation method, and its applications. The invention provides a stably expressed porcine pseudorabies virus gD recombinant protein, the amino acid sequence of which is shown in SEQ ID NO:7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, exhibiting stable expression levels after 48 consecutive passages. This lays a solid foundation for its subsequent applications in the preparation of stable porcine pseudorabies subunit vaccine compositions or in porcine pseudorabies virus vaccine efficacy testing formulations.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

The invention provides a quantitative kit for a porcine epidemic diarrhea virus PEDV S protein. The quantitative detection of the PEDV S protein is realized by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method. The kit comprises a coated elisa plate, an HRP (horse radish peroxidase) labeled monoclonal antibody PEDV-mAb-002, a recombinant PEDV S protein standard substance, a substrate developing solution, a reaction stopping solution, a washing solution and a sample diluent auxiliary reagent. The kit is compared with a standard curve to accurately measure the content of PEDV S protein in a sample. The kit has high sensitivity and high specificity, can accurately detect PEDV S protein at low concentration, has no cross reaction, and ensures the application effect of the kit in actual samples. In performance verification, the kit shows good specificity, sensitivity, precision and correctness, and can meet rapid detection requirements. The kit is simple and convenient to operate, rapid in detection and accurate in result, is suitable for detecting the potency of the PEDV vaccine of the porcine epidemic diarrhea virus, and has relatively high application value and popularization prospect.

The invention belongs to the technical field of vaccine research and development, and particularly relates to a method for testing the efficacy of a porcine pseudorabies GE gene deletion inactivated vaccine, which comprises the following steps of: inoculating a porcine pseudorabies virus HNQYY2012gE strain virus seed (the virus content per 1ml is more than or equal to 108.5 TCID50) into suspension cultured ST cells according to MOI = 0.05, sampling every 12 hours after virus inoculation, counting and observing the cytopathic effect, and determining the efficacy of the inactivated vaccine with the efficacy of the porcine pseudorabies GE gene deletion inactivated vaccine according to the efficacy of the inactivated vaccine with the efficacy of the porcine pseudorabies GE gene deletion inactivated vaccine and the efficacy of the porcine pseudorabies GE gene deletion inactivated vaccine. The method comprises the following steps of: simultaneously measuring the titer of TCID50, sampling, counting and observing the cytopathy condition 42 hours after virus inoculation, simultaneously immunizing and replacing an animal guinea pig and a target animal pig by using a porcine pseudorabies inactivated vaccine (HNQYY2012gE strain), and researching the correlation between the immune antibody level and the challenge protection of the two animals. A basis is provided for the relevance of an efficacy evaluation method in target animal and alternative animal antibody level and challenge protection, the cost of porcine pseudorabies gE gene deletion inactivated vaccine development can be effectively reduced, and the problem that porcine pseudorabies virus negative pigs are very difficult to screen at present can be solved.

The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.

The present invention discloses a strain of Lactobacillus mucosus from guinea pigs JL20 and its application, belonging to the field of biomedicine. Lactobacillus mucosus from guinea pigs JL20 was deposited in the General Microbiology Center of the China National Committee for the Collection of Microorganisms on July 19, 2023, with the deposit number CGMCC No. 27949. Lactobacillus mucosus from guinea pigs JL20 can be used as an adjuvant in leptospira vaccines, and has the effects of enhancing vaccine potency, improving antibody quality, and enhancing the reactivity of antigen-presenting cells. It is also convenient to administer, significantly reduces the vaccine dosage, reduces production costs, is safe and has no side effects, and reduces the production of inflammatory side effects caused by vaccine immunization, and has very important application value.

The invention provides an avian infectious laryngotracheitis virus virulent strain, a challenge model and establishment of a vaccine potency evaluation method, and belongs to the technical field of microorganisms. The invention provides an avian infectious laryngotracheitis virus HB strain (ILTV HB strain) which has strong pathogenicity to chickens, typical symptoms and high morbidity and mortality, and can be used as a virus strain for evaluating vaccine potency and counteracting toxic substances. The invention also establishes a new potency evaluation standard of the avian infectious laryngotracheitis live vaccine, reduces the challenge dose but can improve the morbidity, and increases nucleic acid detection evaluation, and the potency evaluation standard is more scientific and objective in evaluating the effectiveness of the vaccine.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Methods and systems for the multiple detection and / or measurement of biomarkers in a sample are provided herein. These methods and systems can be used for rapid disease detection and / or monitoring, monitoring of vaccine efficacy and immune response, monitoring of therapeutic agents, and / or monitoring of the safety and efficacy of treatments.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The invention provides a method for detecting the in-vitro efficacy of a feline panleucopenia inactivated vaccine based on an ELISA (Enzyme-Linked Immunosorbent Assay) method, which is used for detecting the in-vitro efficacy of the feline panleucopenia inactivated vaccine in triple inactivated vaccines of feline panleucopenia, rhinotracheitis and calicivirus diseases based on a double-antibody sandwich ELISA detection method. The detection method has the advantages of simplicity in operation, good specificity, high sensitivity and short time consumption. The traditional in-vivo potency animal test can be replaced, the adverse factors of many influence factors, poor repeatability, long verification period and the like caused by the tested animal are solved, and high-throughput vaccine potency detection can be realized.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

The present invention provides an organelle-targeted molecular in situ assembly chimera and its application, belonging to the field of molecular technology. The chimera of the present invention comprises, from N-terminus to C-terminus, an organelle-residence structural unit, an assembly structural unit, a tracer structural unit, and a monomeric streptavidin structural unit, each of which is connected by a linker. The chimera constructed by the present invention assembles biological functional molecules in situ in the organelle region and is applied to various vaccine antigen models. It can significantly enhance antigen-specific immune responses in various vaccine antigen models, improve vaccine efficacy, and enhance the immune protection generated by the vaccine.

This invention belongs to the field of biotechnology, specifically relating to a hybridoma cell line secreting monoclonal antibodies against Clostridium perfringens ETX and its applications. Based on natural toxins, this invention establishes an indirect ELISA detection method using a non-toxic ETX single-amino acid site protein mutant. A series of hybridoma cell lines secreting monoclonal antibodies against Clostridium perfringens ETX were screened. These hybridoma cell lines can stably and efficiently secrete both neutralizing monoclonal antibodies and non-neutralizing monoclonal antibodies, and can be mass-produced on a large scale. This invention is the first to establish an antigen ELISA detection method for Clostridium perfringens ETX using monoclonal antibodies. This method features simple sample handling, low cost, rapid reaction, and high specificity. It can also provide a reference for the diagnosis of Clostridium perfringens infection and lay the foundation for research on alternative methods for testing the efficacy of related vaccines.

The invention discloses a method for rapidly quantifying Seneca virus inactivated antigen protein. The method comprises the following steps: establishing a specific purification technology to obtain a Seneca antigen standard substance, and establishing a linear relation equation between the Seneca antigen content and the chromatographic peak area; meanwhile, a pretreatment method for samples which are not suitable for direct sample loading detection in the Seneca inactivated vaccine production process is established, so that the samples which can be used for detection are obtained; further, in order to eliminate the influence of the target protein loss on the detection result in the sample treatment process, determining the sample recovery rate R in different treatment processes through a labeling recovery test; and finally, through a linear equation and the recovery rate R, calculating to obtain the antigen content of the sample at each stage in the Seneca inactivated vaccine production process. The method is used for directly detecting the content of the Seneca inactivated antigen protein, has the advantages of simple detection operation process and high detection result repeatability, is suitable for each stage of the Seneca inactivated vaccine production process, and can effectively control the Seneca inactivated vaccine production process and the vaccine efficacy.

Aspects of the present disclosure relate to functionalized polymers and methods of use thereof. Certain aspects are directed to polymers comprising adjuvants for use in stimulating an immune response. In some cases, provided are polymers comprising inflammasome activators, in some cases also comprising a TLR agonist, which may be formulated in a pharmaceutical composition. Also disclosed are methods for improving vaccine efficacy and immunotherapy efficacy. Certain aspects relate to compositions and methods for stimulation of CD4+ and / or CD8+ T cell responses in a subject.

The invention provides an organelle-targeted molecule in-situ assembly chimera and application thereof, and belongs to the technical field of molecules. The chimera sequentially comprises an organelle residing structural unit, an assembling structural unit, a tracing structural unit and a monomer streptomycin structural unit from an N end to a C end, and all the units are connected through linkers. According to the chimera constructed by the invention, the biological functional molecules are assembled in an organelle area in situ and are applied to various vaccine antigen models, so that the immunoreaction of antigen specificity in the various vaccine antigen models can be remarkably enhanced, the vaccine efficacy is improved, and the immune protection generated by the vaccine is enhanced.

This invention discloses a vaccine potency prediction method based on a self-trained model, relating to the field of medical technology. The method constructs a prediction model by collecting spatiotemporal data such as time and temperature during the storage and distribution of vaccines, and continuously trains and optimizes the model parameters using historical data. The system includes data collection, cleaning, model training, and prediction display. This invention achieves rapid, non-destructive, and automated prediction of vaccine potency, improving the efficiency and safety of vaccine lifecycle management.

Methods and compositions are disclosed for monitoring mutation load, cancer status, vaccine potency with cell-free DNA sequencing following enrichment with a combined set of probes.